\-\ Texto\\:\\ \ \(0\)\
\-\ decreased\\ range\\ of\\ motion\\ of\\ right\\ hip\\ secondary\\ to\\ pain\\.\ \(0\)\
\-\ labs\\ normal\\.\ \(1\)\
\-\ hip\\ replacement\\ is\\ the\\ best\\ treatment\\,\\ however\\ this\\ patient\\ was\\ a\\ poor\\ surgical\\ candidate\\ and\\ was\\ treated\\ with\\ oral\\ pain\\ meds\\ and\\ facet\\ blocks\\.\ \(0\)\
\-\ x\\-ray\\:\\ serpntine\\ sclerotic\\ densities\\ in\\ the\\ both\\ femoral\\ heads\ \(0\)\
\-\ nuclear\\ scan\\:\\ focal\\ areas\\ of\\ photopenia\\ in\\ the\\ femoral\\ heads\\ with\\ surrounding\\ mild\\-to\\-moderate\\ increased\\ uptake\\ in\\ the\\ subcapital\\ areas\\ and\\ acetabuli\\.\\ \ \(0\)\
\-\ mri\\:\\ serpentine\\ areas\\ of\\ hypointensity\\ seen\\ in\\ the\\ bilateral\\ femoral\\ heads\\ on\\ t2\\ images\\.\\ \\ increased\\ t2\\ signal\\ seen\\ in\\ the\\ remaining\\ marrow\\ and\\ femoral\\ necks\\.\ \(0\)\
\-\ bilateral\\ avascular\\ necrosis\\ \\(avn\\)\\ of\\ the\\ femoral\\ heads\ \(0\)\
\-\ avn\\ \\(avascular\\ necrosis\\)\ \(0\)\
\-\ fracture\\ secondary\\ to\\ fall\ \(0\)\
\-\ osteoarthritis\ \(102\)\
\-\ inability\\ to\\ bear\\ weight\\ on\\ right\\ hip\\ with\\ constant\\,\\ severe\\,\\ non\\-radiating\\ pain\\ of\\ abrupt\\ onset\\.\\ \\ patient\\ fell\\ yesterday\\.\ \(0\)\
\-\ male\\ to\\ female\\ ratio\\ for\\ avn\\ is\\ 8\\ to\\ 1\\.\\ etiologies\\ are\\ numerous\\,\\ however\\,\\ in\\ non\\-taumatic\\ cases\\ the\\ etiology\\ is\\ poorly\\ understood\\.\\ \\ glucocorticoid\\ steroid\\ use\\ and\\ excessive\\ alcohol\\ intake\\ are\\ reported\\ to\\ account\\ for\\ more\\ than\\ 90\\ percent\\ of\\ cases\\.\ \(0\)\
\-\ one\\ possible\\ mechanism\\ of\\ steroid\\-induced\\ osteonecrosis\\ involves\\ alterations\\ in\\ circulating\\ lipids\\ with\\ resultant\\ microemboli\\ in\\ the\\ arteries\\ supplying\\ bone\\.\\ a\\ newer\\ theory\\ proposes\\ that\\ steroids\\ induce\\ changes\\ in\\ venous\\ endothelial\\ cells\\,\\ leading\\ to\\ stasis\\,\\ increased\\ intraosseous\\ pressure\\,\\ and\\ eventual\\ necrosis\\.\\ excessive\\ alcohol\\ use\\ and\\ the\\ development\\ of\\ osteonecrosis\\ have\\ been\\ linked\\ for\\ decades\\;\\ fat\\ emboli\\,\\ venous\\ stasis\\,\\ and\\ increased\\ cortisol\\ levels\\ have\\ all\\ been\\ implicated\\ as\\ etiologic\\ factors\\.\\ \\ \ \(0\)\
\-\ patients\\ with\\ sle\\ who\\ have\\ taken\\ glucocorticoids\\ are\\ at\\ greatest\\ risk\\,\\ although\\ occasional\\ cases\\ have\\ been\\ noted\\ in\\ the\\ absence\\ of\\ steroid\\ therapy\\.\\ \\ in\\ addition\\ to\\ their\\ role\\ in\\ patients\\ with\\ sle\\,\\ antiphospholipid\\ antibodies\\ may\\ be\\ associated\\ with\\ an\\ increased\\ risk\\ of\\ osteonecrosis\\ in\\ other\\ individuals\\.\\ fracture\\ or\\ dislocation\\ may\\ cause\\ damage\\ to\\ the\\ extraosseous\\ blood\\ vessels\\ supplying\\ the\\ affected\\ region\\.\\ \ \(0\)\
\-\ osteonecrosis\\ is\\ common\\ in\\ patients\\ with\\ homozygous\\ sickle\\ cell\\ disease\\.\\ approximately\\ 50\\ percent\\ of\\ affected\\ patients\\ develop\\ osteonecrosis\\ by\\ the\\ age\\ of\\ 35\\.\\ \\ gaucher\\ disease\\ results\\ in\\ the\\ accumulation\\ of\\ cerebroside\\-filled\\ cells\\ within\\ the\\ bone\\ marrow\\.\\ this\\ process\\ may\\ lead\\ to\\ compression\\ of\\ the\\ vasculature\\ and\\ subsequent\\ osteonecrosis\\.\\ \\ \\ osteonecrosis\\ can\\ occur\\ following\\ renal\\ transplantation\\,\\ but\\ usually\\ multifocal\\.\\ ther\\ is\\ increased\\ prevalence\\ with\\ thrombophillic\\ disorders\\ such\\ as\\ the\\ factor\\ v\\ leiden\\ mutation\\.\\ \\ hiv\\ may\\ confer\\ an\\ increased\\ risk\\ of\\ developing\\ osteonecrosis\\ of\\ the\\ femoral\\ head\\ as\\ well\\ as\\ individuals\\ undergoing\\ radiation\\ therapy\\.\\ \\ \ \(0\)\
\-\ there\\ are\\ two\\ types\\ of\\ osteonecrosis\\ limited\\ to\\ children\\:\\ idiopathic\\ osteonecrosis\\ of\\ the\\ femoral\\ head\\ \\(legg\\-calv\\?\\-perthes\\ disease\\)\\;\\ and\\ osteonecrosis\\ occurring\\ in\\ children\\,\\ usually\\ adolescents\\,\\ with\\ a\\ slipped\\ capital\\ femoral\\ epiphysis\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ osteonecrosis\\:\\ 0\\.49828395483009486\ \(0\)\
\-\ femoral\\:\\ 0\\.2465320554307593\ \(0\)\
\-\ heads\\:\\ 0\\.17886699474841244\ \(0\)\
\-\ the\\:\\ 0\\.16546473750166799\ \(0\)\
\-\ in\\:\\ 0\\.16503170663547484\ \(0\)\
\-\ increased\\:\\ 0\\.1569459891426508\ \(0\)\
\-\ of\\:\\ 0\\.15416588852100643\ \(0\)\
\-\ avn\\:\\ 0\\.1487126555218101\ \(0\)\
\-\ to\\:\\ 0\\.12438600764864045\ \(0\)\
\-\ steroid\\:\\ 0\\.11989099756688072\ \(0\)\
\-\ supplying\\:\\ 0\\.10432677397427854\ \(0\)\
\-\ stasis\\:\\ 0\\.09775624092867304\ \(0\)\
\-\ hip\\:\\ 0\\.09555086574932253\ \(0\)\
\-\ necrosis\\:\\ 0\\.09507988450324158\ \(0\)\
\-\ patients\\:\\ 0\\.09329930903114374\ \(0\)\
\-\ excessive\\:\\ 0\\.08943349737420622\ \(0\)\
\-\ risk\\:\\ 0\\.08887681085090648\ \(0\)\
\-\ sle\\:\\ 0\\.08801412147643498\ \(0\)\
\-\ individuals\\:\\ 0\\.0867210868930066\ \(0\)\
\-\ and\\:\\ 0\\.08567682527444978\ \(0\)\
\-\ areas\\:\\ 0\\.08445013637690514\ \(0\)\
\-\ cases\\:\\ 0\\.08366325157454972\ \(0\)\
\-\ may\\:\\ 0\\.08346060403110436\ \(0\)\
\-\ have\\:\\ 0\\.08285082909383\ \(0\)\
\-\ avascular\\:\\ 0\\.08246191666033557\ \(0\)\
\-\ percent\\:\\ 0\\.08200759668592492\ \(0\)\
\-\ with\\:\\ 0\\.08118842242245371\ \(0\)\
\-\ alcohol\\:\\ 0\\.07664476752740192\ \(0\)\
\-\ been\\:\\ 0\\.07246926629285907\ \(0\)\
\-\ marrow\\:\\ 0\\.06891281225105932\ \(0\)\
\-\ affected\\:\\ 0\\.06820354690329532\ \(0\)\
\-\ children\\:\\ 0\\.06794624716019368\ \(0\)\
\-\ as\\:\\ 0\\.06662755521160542\ \(0\)\
\-\ serpntine\\:\\ 0\\.0663072893707666\ \(0\)\
\-\ thrombophillic\\:\\ 0\\.0663072893707666\ \(0\)\
\-\ cells\\:\\ 0\\.06389227738565935\ \(0\)\
\-\ use\\:\\ 0\\.06344884696303789\ \(0\)\
\-\ subcapital\\:\\ 0\\.06336015488368205\ \(0\)\
\-\ lipids\\:\\ 0\\.06336015488368205\ \(0\)\
\-\ microemboli\\:\\ 0\\.06336015488368205\ \(0\)\
\-\ proposes\\:\\ 0\\.06336015488368205\ \(0\)\
\-\ antiphospholipid\\:\\ 0\\.06336015488368205\ \(0\)\
\-\ are\\:\\ 0\\.06293227161916141\ \(0\)\
\-\ extraosseous\\:\\ 0\\.05964720453954139\ \(0\)\
\-\ confer\\:\\ 0\\.05964720453954139\ \(0\)\
\-\ venous\\:\\ 0\\.059204539277392165\ \(0\)\
\-\ acetabuli\\:\\ 0\\.058321995200879696\ \(0\)\
\-\ necks\\:\\ 0\\.058321995200879696\ \(0\)\
\-\ etiologic\\:\\ 0\\.058321995200879696\ \(0\)\
\-\ homozygous\\:\\ 0\\.058321995200879696\ \(0\)\
\-\ glucocorticoid\\:\\ 0\\.057201546669941615\ \(0\)\
\-\ alterations\\:\\ 0\\.057201546669941615\ \(0\)\
\-\ induce\\:\\ 0\\.057201546669941615\ \(0\)\
\-\ leiden\\:\\ 0\\.057201546669941615\ \(0\)\
\-\ is\\:\\ 0\\.05677370153913304\ \(0\)\
\-\ photopenia\\:\\ 0\\.05623097000516192\ \(0\)\
\-\ yesterday\\:\\ 0\\.05623097000516192\ \(0\)\
\-\ circulating\\:\\ 0\\.05623097000516192\ \(0\)\
\-\ newer\\:\\ 0\\.05460904485673904\ \(0\)\
\-\ ther\\:\\ 0\\.05460904485673904\ \(0\)\
\-\ blocks\\:\\ 0\\.05391628014713887\ \(0\)\
\-\ implicated\\:\\ 0\\.05391628014713887\ \(0\)\
\-\ cortisol\\:\\ 0\\.05328383551807735\ \(0\)\
\-\ disease\\:\\ 0\\.05221323741386767\ \(0\)\
\-\ usually\\:\\ 0\\.05220414377513934\ \(0\)\
\-\ theory\\:\\ 0\\.05216338698713927\ \(0\)\
\-\ endothelial\\:\\ 0\\.05216338698713927\ \(0\)\
\-\ understood\\:\\ 0\\.05166191036965447\ \(0\)\
\-\ glucocorticoids\\:\\ 0\\.051192810322359575\ \(0\)\
\-\ antibodies\\:\\ 0\\.051192810322359575\ \(0\)\
\-\ gaucher\\:\\ 0\\.05075215856182878\ \(0\)\
\-\ eventual\\:\\ 0\\.05033670103099278\ \(0\)\
\-\ adolescents\\:\\ 0\\.0495708851739367\ \(0\)\
\-\ head\\:\\ 0\\.04945808622667837\ \(0\)\
\-\ secondary\\:\\ 0\\.0491515351629428\ \(0\)\
\-\ however\\:\\ 0\\.049081701292958205\ \(0\)\
\-\ serpentine\\:\\ 0\\.048555021583904\ \(0\)\
\-\ transplantation\\:\\ 0\\.048245675835275004\ \(0\)\
\-\ t2\\:\\ 0\\.047708844014016205\ \(0\)\
\-\ capital\\:\\ 0\\.04766388317418768\ \(0\)\
\-\ therapy\\:\\ 0\\.047645593489378024\ \(0\)\
\-\ intraosseous\\:\\ 0\\.04738956654390822\ \(0\)\
\-\ fracture\\:\\ 0\\.04712894153086277\ \(0\)\
\-\ decades\\:\\ 0\\.046870165064097205\ \(0\)\
\-\ mutation\\:\\ 0\\.04662375068685213\ \(0\)\
\-\ hypointensity\\:\\ 0\\.04638541694188967\ \(0\)\
\-\ slipped\\:\\ 0\\.04638541694188967\ \(0\)\
\-\ bear\\:\\ 0\\.04571399887902643\ \(0\)\
\-\ linked\\:\\ 0\\.04571399887902643\ \(0\)\
\-\ abrupt\\:\\ 0\\.04550330215591405\ \(0\)\
\-\ candidate\\:\\ 0\\.04529854134819044\ \(0\)\
\-\ meds\\:\\ 0\\.04529854134819044\ \(0\)\
\-\ intake\\:\\ 0\\.04529854134819044\ \(0\)\
\-\ prevalence\\:\\ 0\\.04529854134819044\ \(0\)\
\-\ bone\\:\\ 0\\.045246277266039754\ \(0\)\
\-\ constant\\:\\ 0\\.04471674868710311\ \(0\)\
\-\ bilateral\\:\\ 0\\.04456677048747882\ \(0\)\
\-\ pain\\:\\ 0\\.04451024083110977\ \(0\)\
\-\ resultant\\:\\ 0\\.043516861901101656\ \(0\)\
\-\ role\\:\\ 0\\.043516861901101656\ \(0\)\
\-\ inability\\:\\ 0\\.042766864391941856\ \(0\)\
\-\ account\\:\\ 0\\.0422180356331113\ \(0\)\
\-\ occurring\\:\\ 0\\.041832005381294855\ \(0\)\
\-\ ratio\\:\\ 0\\.04158559100404978\ \(0\)\
\-\ etiologies\\:\\ 0\\.04158559100404978\ \(0\)\
\-\ densities\\:\\ 0\\.0414654473101691\ \(0\)\
\-\ greatest\\:\\ 0\\.0414654473101691\ \(0\)\
\-\ sickle\\:\\ 0\\.04100379834296246\ \(0\)\
\-\ hiv\\:\\ 0\\.04100379834296246\ \(0\)\
\-\ epiphysis\\:\\ 0\\.04100379834296246\ \(0\)\
\-\ vasculature\\:\\ 0\\.040783523061921484\ \(0\)\
\-\ emboli\\:\\ 0\\.040675839196224084\ \(0\)\
\-\ damage\\:\\ 0\\.04036204105665061\ \(0\)\
\-\ multifocal\\:\\ 0\\.0402603816653881\ \(0\)\
\-\ facet\\:\\ 0\\.04016012451739984\ \(0\)\
\-\ accumulation\\:\\ 0\\.04006123145461585\ \(0\)\
\-\ occasional\\:\\ 0\\.039963665855626905\ \(0\)\
\-\ developing\\:\\ 0\\.039678589004300775\ \(0\)\
\-\ remaining\\:\\ 0\\.039404272374021304\ \(0\)\
\-\ nuclear\\:\\ 0\\.039226982414281686\ \(0\)\
\-\ mechanism\\:\\ 0\\.0390539140478012\ \(0\)\
\-\ seen\\:\\ 0\\.039040256928436406\ \(0\)\
\-\ factor\\:\\ 0\\.03888487089421029\ \(0\)\
\-\ types\\:\\ 0\\.03855814047336269\ \(0\)\
\-\ develop\\:\\ 0\\.03816935646967032\ \(0\)\
\-\ osteoarthritis\\:\\ 0\\.037872640659909126\ \(0\)\
\-\ for\\:\\ 0\\.037700740517868314\ \(0\)\
\-\ undergoing\\:\\ 0\\.03765779167847784\ \(0\)\
\-\ poorly\\:\\ 0\\.03744911147028741\ \(0\)\
\-\ replacement\\:\\ 0\\.03724625566270302\ \(0\)\
\-\ fell\\:\\ 0\\.036920258067181404\ \(0\)\
\-\ lead\\:\\ 0\\.036920258067181404\ \(0\)\
\-\ leading\\:\\ 0\\.03685677706987643\ \(0\)\
\-\ disorders\\:\\ 0\\.03660825617820143\ \(0\)\
\-\ steroids\\:\\ 0\\.03642728762736675\ \(0\)\
\-\ involves\\:\\ 0\\.03607833127395254\ \(0\)\
\-\ dislocation\\:\\ 0\\.03596563866016012\ \(0\)\
\-\ factors\\:\\ 0\\.035072350116427356\ \(0\)\
\-\ idiopathic\\:\\ 0\\.035072350116427356\ \(0\)\
\-\ numerous\\:\\ 0\\.035023071771813505\ \(0\)\
\-\ poor\\:\\ 0\\.03497412527042063\ \(0\)\
\-\ sclerotic\\:\\ 0\\.03478157022205494\ \(0\)\
\-\ fall\\:\\ 0\\.03454783535607513\ \(0\)\
\-\ their\\:\\ 0\\.03441111920027665\ \(0\)\
\-\ development\\:\\ 0\\.03427692717978055\ \(0\)\
\-\ addition\\:\\ 0\\.03356002787803536\ \(0\)\
\-\ etiology\\:\\ 0\\.03340114662339062\ \(0\)\
\-\ best\\:\\ 0\\.033361963089200405\ \(0\)\
\-\ oral\\:\\ 0\\.03320730772304075\ \(0\)\
\-\ 90\\:\\ 0\\.03313119678686797\ \(0\)\
\-\ taken\\:\\ 0\\.03313119678686797\ \(0\)\
\-\ limited\\:\\ 0\\.03309343811499596\ \(0\)\
\-\ absence\\:\\ 0\\.03305587457924999\ \(0\)\
\-\ arteries\\:\\ 0\\.0329075321245627\ \(0\)\
\-\ levels\\:\\ 0\\.03287091477765018\ \(0\)\
\-\ results\\:\\ 0\\.032308816224189914\ \(0\)\
\-\ range\\:\\ 0\\.03217483034751293\ \(0\)\
\-\ vessels\\:\\ 0\\.03217483034751293\ \(0\)\
\-\ motion\\:\\ 0\\.03214171626750661\ \(0\)\
\-\ uptake\\:\\ 0\\.03188209838437906\ \(0\)\
\-\ an\\:\\ 0\\.031710110348937046\ \(0\)\
\-\ pressure\\:\\ 0\\.03157009649539908\ \(0\)\
\-\ subsequent\\:\\ 0\\.03138912794456441\ \(0\)\
\-\ process\\:\\ 0\\.03109717994605294\ \(0\)\
\-\ occur\\:\\ 0\\.030493408048412392\ \(0\)\
\-\ compression\\:\\ 0\\.03036291032430564\ \(0\)\
\-\ reported\\:\\ 0\\.029863158354590143\ \(0\)\
\-\ 50\\:\\ 0\\.028956248035459573\ \(0\)\
\-\ weight\\:\\ 0\\.02891374190268693\ \(0\)\
\-\ was\\:\\ 0\\.028900063836834078\ \(0\)\
\-\ labs\\:\\ 0\\.028725481733127136\ \(0\)\
\-\ this\\:\\ 0\\.028494405377396628\ \(0\)\
\-\ cause\\:\\ 0\\.028246064398096266\ \(0\)\
\-\ although\\:\\ 0\\.02822675886751828\ \(0\)\
\-\ possible\\:\\ 0\\.028093037104065622\ \(0\)\
\-\ surrounding\\:\\ 0\\.027652385343534824\ \(0\)\
\-\ right\\:\\ 0\\.02749295475816864\ \(0\)\
\-\ radiation\\:\\ 0\\.02747638333063823\ \(0\)\
\-\ patient\\:\\ 0\\.026971227897881072\ \(0\)\
\-\ such\\:\\ 0\\.026670682810993343\ \(0\)\
\-\ onset\\:\\ 0\\.026624139249673395\ \(0\)\
\-\ approximately\\:\\ 0\\.02645598494083927\ \(0\)\
\-\ severe\\:\\ 0\\.02624744729333747\ \(0\)\
\-\ age\\:\\ 0\\.026030460195111942\ \(0\)\
\-\ treated\\:\\ 0\\.025819763471999563\ \(0\)\
\-\ renal\\:\\ 0\\.025819763471999563\ \(0\)\
\-\ fat\\:\\ 0\\.02579212645014948\ \(0\)\
\-\ decreased\\:\\ 0\\.0256826173657121\ \(0\)\
\-\ changes\\:\\ 0\\.02505810224665967\ \(0\)\
\-\ on\\:\\ 0\\.025044669688718334\ \(0\)\
\-\ following\\:\\ 0\\.024873455704522728\ \(0\)\
\-\ focal\\:\\ 0\\.024800890762491232\ \(0\)\
\-\ region\\:\\ 0\\.024800890762491232\ \(0\)\
\-\ all\\:\\ 0\\.024681536225333492\ \(0\)\
\-\ two\\:\\ 0\\.024622585959057825\ \(0\)\
\-\ scan\\:\\ 0\\.02459913907424326\ \(0\)\
\-\ blood\\:\\ 0\\.024079737594432247\ \(0\)\
\-\ one\\:\\ 0\\.023739129311632034\ \(0\)\
\-\ cell\\:\\ 0\\.023718362074677264\ \(0\)\
\-\ common\\:\\ 0\\.023513889294850494\ \(0\)\
\-\ signal\\:\\ 0\\.02350381510337003\ \(0\)\
\-\ than\\:\\ 0\\.02350381510337003\ \(0\)\
\-\ who\\:\\ 0\\.02345365253029454\ \(0\)\
\-\ both\\:\\ 0\\.02312143079131262\ \(0\)\
\-\ more\\:\\ 0\\.02276725295476312\ \(0\)\
\-\ noted\\:\\ 0\\.02198326576826883\ \(0\)\
\-\ associated\\:\\ 0\\.02185375627540666\ \(0\)\
\-\ can\\:\\ 0\\.02175811636936569\ \(0\)\
\-\ other\\:\\ 0\\.021532052773743947\ \(0\)\
\-\ mri\\:\\ 0\\.02128308040668201\ \(0\)\
\-\ but\\:\\ 0\\.020503186148588447\ \(0\)\
\-\ surgical\\:\\ 0\\.02015204406907994\ \(0\)\
\-\ well\\:\\ 0\\.020076263768519818\ \(0\)\
\-\ female\\:\\ 0\\.02000748578619046\ \(0\)\
\-\ treatment\\:\\ 0\\.019750707043878858\ \(0\)\
\-\ images\\:\\ 0\\.01917908727177134\ \(0\)\
\-\ within\\:\\ 0\\.019096269877646826\ \(0\)\
\-\ male\\:\\ 0\\.01846062355606102\ \(0\)\
\-\ that\\:\\ 0\\.01799309559225653\ \(0\)\
\-\ by\\:\\ 0\\.017607309314907324\ \(0\)\
\-\ normal\\:\\ 0\\.016928790639806585\ \(0\)\
\-\ be\\:\\ 0\\.016819609028803136\ \(0\)\
\-\ there\\:\\ 0\\.01649773176438154\ \(0\)\
\-\ at\\:\\ 0\\.015660846308578162\ \(0\)\
\-\ or\\:\\ 0\\.01442400573110866\ \(0\)\
